21
Lee Fang Yu, Lee Fang Chen, Yang Chang An, Yong Ma Wei, Wu Xu Ai, Ye Wu Qiu, Hua Xiao Xu: Condensed tricyclic heterocyclic compound. Yung Shin Pharmaceutical, April 9, 2003: JP2003-104987

PROBLEM TO BE SOLVED: To provide a new guanomine condensed tricyclic heterocyclic compound having antitumor activity.SOLUTION: The compound is expressed by formula (R1 is H or an alkyl; R2 is H, an alkyl, an alkenyl, an aryl, a heteroaryl, a cyclyl or a heterocyclyl; R3 and R4 are each independently ...


22
Sekiguchi Nagahisa, Makino Toshihiko, Ezaki Toru, Emura Takeshi, Kito Yasushi: Tricyclic heterocyclic compound having nos inhibiting action. Chugai Pharmaceut, December 8, 1998: JP1998-324677

PROBLEM TO BE SOLVED: To obtain the subject new compound having a nitric oxide synthase(NOS) inhibiting action and usable as a therapeutic agent for cerebrovascular diseases, head injury, Parkinson's disease, Alzheimer's disease, etc. SOLUTION: This compound is represented by formula I [R1 is a tric ...


23
Ohashi Norihiko, Mizuide Haruo, Ishida Toru: Production of tricyclic heterocyclic compound. Takeda Chem, September 29, 1998: JP1998-259184

PROBLEM TO BE SOLVED: To obtain a compound useful as a starting raw material for a tricyclic heterocyclic compound having an excellent tachykinin receptor-antagonizing action, especially a substance P receptor-antagonizing action. SOLUTION: A compound of formula II (R' is a substitutable 1-4C alkyl; ...


24
Akimoto Hiroshi, Otsu Koichiro, Miwa Tetsuo: Condensed tricyclic heterocyclic compound, its production, use and intermediate. Takeda Chem, August 3, 1992: JP1992-211063

PURPOSE: To obtain a new compound useful as an antitumor agent. CONSTITUTION: A compound, e.g. tert-butyl 4-[2-(2-amino-7,8-dihydropyrido[2,3-d] pyfrolo[3,2-e] pyrimidin-6-yl)ethyl]benzoate expressed by formula I {rungs A1 and A2 are 5 to 7-membered rung which may have substituent group; B is (subst ...


25
TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS. Nissan Chemical, July 17, 2014: US20140200344-A1

Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a L2a, L3a and na are as defined in the description.


26
TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS. NISSAN CHEMICAL, April 14, 2016: US20160102102-A1

This disclosure relates to novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities. A tricyclic heterocyclic compound represented by the formula (Ib), wherein the rings Ab and Bb, Xb, Yb, R1b, R2b, R3b, L1b, L2b, L3b and nb are as defined in the specifi ...


27
METHOD FOR PRODUCING TRICYCLIC HETEROCYCLIC COMPOUND. Daiichi Sankyo Company, May 19, 2016: US20160137644-A1

It is an object of the present invention to provide a method for producing a high-purity tricyclic heterocyclic compound represented by formula (I), which is useful as a production intermediate for a pharmaceutical agent, wherein the method is an efficient production method with short steps and with ...


28
NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND. MITSUBISHI TANABE PHARMA CORPORATION, December 29, 2016: US20160376289-A1

The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or ...


29
In-Source Chemical Modification of Non Polar Analytes Using Atmospheric Pressure Chemical Ionisation Source. October 19, 2017: US20170301530-A1

A method for analysing an aliphatic compound by mass spectrometry which comprises: (i) ionising an aliphatic compound in the presence of a heterocyclic modifier; and (ii) mass analysing the resulting ions to obtain mass spectrometric data.